| ESR1 alterations and metastasis in estrogen receptor positive breast cancer JT Lei, X Gou, S Seker, MJ Ellis Journal of Cancer Metastasis and Treatment 5 (38), 2019 | 105 | 2019 |
| Neurofibromin is an estrogen receptor-α transcriptional co-repressor in breast cancer ZY Zheng, M Anurag, JT Lei, J Cao, P Singh, J Peng, H Kennedy, ... Cancer Cell 37 (3), 387-402. e7, 2020 | 67 | 2020 |
| Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer NB Punturi, S Seker, V Devarakonda, A Mazumder, R Kalra, CH Chen, ... Nature communications 12 (1), 2940, 2021 | 15 | 2021 |
| Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast CancerA Diagnostic Gene Signature for ESR1 … X Gou, M Anurag, JT Lei, BJ Kim, P Singh, S Seker, D Fandino, A Han, ... Cancer research 81 (24), 6259-6272, 2021 | 12 | 2021 |
| Molecular portraits of cell cycle checkpoint kinases in cancer evolution, progression, and treatment responsiveness E Oropeza, S Seker, S Carrel, A Mazumder, A Jimenez, S VandenHeuvel, ... | 1 | 2020 |
| Abstract P6-04-04: Functional characterization of ESR1 fusions in breast cancer X Gou, JT Lei, S Seker, BJ Kim, S Rehman, AV Lee, DR Robinson, ... Cancer Research 80 (4_Supplement), P6-04-04-P6-04-04, 2020 | 1 | 2020 |
| NF1 as an estrogen receptor-α co-repressor in breast cancer EC Chang, zeyi Zheng, M Anurag, J Gao, B Cakar, X Du, J Li, P Lavere, ... Cancer Research 78 (13_Supplement), 1814-1814, 2018 | 1 | 2018 |
| Abstract P3-10-02: Cell cycle dysregulation in breast cancer: why the details matter S Seker, E Oropeza, S Carrel, A Mazumder, N Punturi, J Lei, M Anurag, ... Cancer Research 83 (5_Supplement), P3-10-02-P3-10-02, 2023 | | 2023 |
| Differential impact of mutations in cell cycle checkpoint kinases on breast cancer presentation and prognosis S Seker, NB Punturi, S Carell, AM Mazumder, N Fusco, MN Bainbridge, ... bioRxiv, 2020.10. 29.361352, 2022 | | 2022 |
| The integration of a structure-function rule and a transcriptional signature to assign ESR1 fusion activity in metastatic breast cancer X Gou, M Anurag, JT Lei, S Seker, AV Lee, DR Robinson, MJ Ellis Cancer Research 81 (13_Supplement), 742-742, 2021 | | 2021 |
| Abstract PD8-05: Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer S Haricharan, N Punturi, S Seker, V Devarakonda, R Kalra, CH Chen, ... Cancer Research 81 (4_Supplement), PD8-05-PD8-05, 2021 | | 2021 |
| Abstract PS17-03: Recurrent active ESR1 fusions render a diagnostic transcriptional signature in metastatic breast cancer X Gou, M Anurag, JT Lei, P Singh, S Seker, AV Lee, DR Robinson, ... Cancer Research 81 (4_Supplement), PS17-03-PS17-03, 2021 | | 2021 |
| Differential impact of mutations in cell cycle checkpoint kinases on breast cancer presentation and prognosis S Seker, NB Punturi, S Carell, AM Mazumder, N Fusco, MN Bainbridge, ... bioRxiv, 2020.10. 29.361352, 2020 | | 2020 |
| Recurrent transcriptionally active ESR1 fusions render therapeutic vulnerabilities to kinase inhibition in advanced breast cancer X Gou, J Lei, BJ Kim, M Anurag, S Seker, S Rehman, AV Lee, K White, ... Cancer Research 80 (16_Supplement), 5677-5677, 2020 | | 2020 |
| Functional significance of ESR1 fusions with diverse gene partners in endocrine therapy resistant breast cancer JT Lei, X Gou, S Seker, V Devorakonda, KR Holloway, AV Lee, ... Cancer Research 79 (13_Supplement), 3479-3479, 2019 | | 2019 |
| Evaluating preclinical efficacy of anti-HER2 drug combinations using ER+/HER2 mutant models V Devarakonda, LT Williams, S Seker, JT Lei, P Singh, A Han, M Anurag, ... Cancer Research 79 (13_Supplement), 850-850, 2019 | | 2019 |
| Abstract P6-17-15: Evaluating preclinical efficacy of anti-HER2 drug combinations using ER+/HER2 mutant models SM Kavuri, V Devarakonda, LC Williams, S Seker, JT Lei, P Singh, A Han, ... Cancer Research 79 (4_Supplement), P6-17-15-P6-17-15, 2019 | | 2019 |
| Abstract P5-04-01: Functional and therapeutic significance of ESR1 fusions in metastatic ER+ breast cancer JT Lei, X Gou, S Seker, S Haricharan, AV Lee, DR Robinson, MJ Ellis Cancer Research 79 (4 Supplement), P5-04-01-P5-04-01, 2019 | | 2019 |
Matthew J. EllisPhysician Scientist, OncologistVerified email at progendis.com
